BioVale LIP

Documentation

Metabolic effect of the berberin-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.

Fogacci F1, Grassi D2,3, Rizzo M4,3, Cicero AFG1,3.

Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy.

Italian Nutraceutical Society (SINut), Bologna, Italy.

Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.

The aim of this study is to evaluate the impact of a combination of berberine and silymarin on serum lipids and fasting plasma glucose (FPG) through a systematic review of the literature and meta-analysis of the clinic available randomized, double-blind, placebo-controlled trials (RCT). A systematic literature search in the SCOPUS, PubMed-Medline, ISI Web of Science and Google Scholar databases was conducted until October 2, 2018, in order to identify RCTs evaluating changes in plasma concentrations of total cholesterol (CT), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and FPG during treatment with berberine and silymarin in combination. Two review authors independently extracted data on characteristics, methods and results of the study. The synthesis of quantitative data was performed using a random effect model. We identified five eligible RCTs, with a total of 497 subjects included. The combined treatment of berberine and silymarin had a positive effect on the

CT (mean difference [MD]: -25.3, 95% CI [-39.2, -11.4] mg / dl; p <0.001), TG (MD: -28, 95% CI [-35.3, -20.6] mg / dl; p <0.001),

HDL-C [MD: +6, 95% IC [3,2, 8,8] mg / dl; p <0,001),

LDL-C (MD: -29,1, 95% IC [-39,7, -18,6] mg / dl; p <0,001) and

FPG (MD: -7,5, IC al 95% [-13, -1,9 ] mg / dl; p = 0,008). The mentioned results suggest that the concomitant administration of berberine and silymarin is associated with a beneficial improvement in lipid and glucose profile, suggesting the possible use of this nutraceutical combination to promote cardiometabolic health.

A recent study presented at the AHA, the world’s leading cardiology congress, highlighted the protective role of chlorogenic acid, contained in Biovale LIP, in endothelial damage caused by post-prandial hyperlipidemia.